文献速递认知障碍与痴呆

常染色体显性阿尔茨海默病年轻成人中淀粉样蛋白与tau蛋白积累的关联

Association Between Amyloid and Tau Accumulation in Young Adults With Autosomal Dominant Alzheimer Disease.
PubMed 文献 · JAMA Neurol · 2018-01-01

这项横断面影像研究纳入24名早老素1(PSEN1)E280A突变家族成员,包括12名携带者(9名认知正常、3名轻度认知障碍)和12名认知正常非携带者,评估淀粉样蛋白PET与tau PET的关联。结果显示认知正常携带者在20多岁末即出现皮层淀粉样蛋白升高,tau沉积在预期临床发病前约6年出现在内侧颞叶,且tau沉积与认知表现较差相关。

要点

  • 认知正常PSEN1 E280A携带者在20多岁末即出现平均皮层淀粉样蛋白分布容积比升高。
  • tau沉积在预期阿尔茨海默病临床发病前约6年出现于携带者内侧颞叶区域。
  • 在携带者中,较高的tau沉积与较差的简易精神状态检查及词汇延迟回忆表现相关。

核心结论

  • 研究结果提示分子标志物可在认知仍正常的个体中刻画阿尔茨海默病相关生物学改变。
  • 作者认为tau PET影像可能有助于识别阿尔茨海默病临床高风险的个体并追踪疾病进展。

研究设计与样本

  • 横断面影像研究,利用一个常染色体显性阿尔茨海默病同质家族的数据。
  • 共纳入24名PSEN1 E280A家族成员(年龄范围28-55岁),包括12名携带者(9名认知正常、3名轻度认知障碍)和12名认知正常非携带者。

主要发现

  • 24名个体的平均(标准差)年龄为38.0(7.4)岁,约比携带者预期临床症状出现年龄年轻6岁。
  • 认知正常突变携带者在20多岁末即出现平均皮层 Pittsburgh 化合物B分布容积比水平升高;9名年龄大于30岁的携带者中有7名达到淀粉样蛋白沉积阈值(分布容积比水平>1.2)。
  • 在该家族中,淀粉样蛋白阳性突变携带者在阿尔茨海默病临床发病前6年即可见内侧颞叶区域tau沉积水平升高。
  • 新皮层中明显的tau沉积仅见于1名认知正常携带者和轻度认知障碍携带者。
  • 在认知正常携带者中,β-淀粉样蛋白摄取水平在预期轻度认知障碍发病前约15年即出现弥漫性升高。

关键数值与推荐

  • 在携带者中,较高的tau沉积与较差的简易精神状态检查表现相关(内嗅皮层:r=-0.60,P=.04;下颞叶:r=-0.54,P=.06)。
  • 在携带者中,较高的tau沉积与较差的阿尔茨海默病注册联盟词汇表延迟回忆表现相关(内嗅皮层:r=-0.86,P<.001;下颞叶:r=-0.70,P=.01)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: It is critically important to improve our ability to diagnose and track Alzheimer disease (AD) as early as possible. Individuals with autosomal dominant forms of AD can provide clues as to which and when biological changes are reliably present prior to the onset of clinical symptoms. OBJECTIVE: To characterize the associations between amyloid and tau deposits in the brains of cognitively unimpaired and impaired carriers of presenilin 1 (PSEN1) E280A mutation. DESIGN, SETTING, AND PARTICIPANTS: In this cross-sectional imaging study, we leveraged data from a homogeneous autosomal dominant AD kindred, which allowed us to examine measurable tau deposition as a function of individuals' proximity to the expected onset of dementia. Cross-sectional measures of carbon 11-labeled Pittsburgh Compound B positron emission tomography (PET) and flortaucipir F 18 (previously known as AV 1451, T807) PET imaging were assessed in 24 PSEN1 E280A kindred members (age range, 28-55 years), including 12 carriers, 9 of whom were cognitively unimpaired and 3 of whom had mild cognitive impairment, and 12 cognitively unimpaired noncarriers. MAIN OUTCOMES AND MEASURES: We compared carbon 11-labeled Pittsburgh Compound B PET cerebral with cerebellar distribution volume ratios as well as flortaucipir F 18 PET cerebral with cerebellar standardized uptake value ratios in mutation carriers and noncarriers. Spearman correlations characterized the associations between age and mean cortical Pittsburgh Compound B distribution volume ratio levels or regional flortaucipir standardized uptake value ratio levels in both groups. RESULTS: Of the 24 individuals, the mean (SD) age was 38.0 (7.4) years, or approximately 6 years younger than the expected onset of clinical symptoms in carriers. Compared with noncarriers, cognitively unimpaired mutation carriers had elevated mean cortical Pittsburgh Compound B distribution volume ratio levels in their late 20s, and 7 of 9 carriers older than 30 years reached the threshold for amyloidosis (distribution volume ratio level > 1.2). Elevated levels of tau deposition were seen within medial temporal lobe regions in amyloid-positive mutation carriers 6 years before clinical onset of AD in this kindred. Substantial tau deposition in the neocortex was only observed in 1 unimpaired carrier and in those with mild cognitive impairment. β-Amyloid uptake levels were diffusely elevated in unimpaired carriers approximately 15 years prior to expected onset of mild cognitive impairment. In carriers, higher levels of tau deposition were associated with worse performance on the Mini-Mental State Examination (entorhinal cortex: r = -0.60; P = .04; inferior temporal lobe: r = -0.54; P = .06) and the Consortium to Establish a Registry for Alzheimer Disease Word List Delayed Recall (entorhinal cortex: r = -0.86; P < .001; inferior temporal lobe: r = -0.70; P = .01). CONCLUSIONS AND RELEVANCE: The present findings add to the growing evidence that molecular markers can characterize biological changes associated with AD in individuals who are still cognitively unimpaired. The findings also suggest that tau PET imaging may be useful as a biomarker to distinguish individuals at high risk to develop the clinical symptoms of AD and to track disease progression.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Quiroz YT, Sperling RA, Norton DJ, et al. Association Between Amyloid and Tau Accumulation in Young Adults With Autosomal Dominant Alzheimer Disease. JAMA Neurol. 2018. PMID: 29435558. doi:10.1001/jamaneurol.2017.4907

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。